key: cord-0931478-kh6hj9gk authors: Declercq, Jozefien; Bosteels, Cedric; Van Damme, Karel; De Leeuw, Elisabeth; Maes, Bastiaan; Vandecauter, Ans; Vermeersch, Stefanie; Delporte, Anja; Demeyere, Bénédicte; Vuylsteke, Marnik; Lalla, Marianna; Smart, Trevor; Detalle, Laurent; Bouw, René; Streffer, Johannes; Degeeter, Thibo; Vergotte, Marie; Guisez, Tanguy; Van Braeckel, Eva; Van Der Straeten, Catherine; Lambrecht, Bart N. title: Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial date: 2020-11-19 journal: Trials DOI: 10.1186/s13063-020-04884-0 sha: 32c2ae6a3d22bebea0c1c81fa7409dc9483b93f2 doc_id: 931478 cord_uid: kh6hj9gk OBJECTIVES: Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation parameters. The purpose of this study is to investigate the efficacy and safety of Zilucoplan in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. TRIAL DESIGN: This is a phase 2 academic, prospective, 2:1 randomized, open-label, multi-center interventional study. PARTICIPANTS: Adult patients (≥18y old) will be recruited at specialized COVID-19 units and ICUs at 9 Belgian hospitals. The main eligibility criteria are as follows: 1) Inclusion criteria: a. Recent (≥6 days and ≤16 days) SARS-CoV-2 infection. b. Chest CT scan showing bilateral infiltrates within the last 2 days prior to randomisation. c. Acute hypoxia (defined as PaO(2)/FiO(2) below 350 mmHg or SpO2 below 93% on minimal 2 L/min supplemental oxygen). d. Signs of cytokine release syndrome characterized by either high serum ferritin, or high D-dimers, or high LDH or deep lymphopenia or a combination of those. 2) Exclusion criteria: e. Mechanical ventilation for more than 24 hours prior to randomisation. f. Active bacterial or fungal infection. g. History of meningococcal disease (due to the known high predisposition to invasive, often recurrent meningococcal infections of individuals deficient in components of the alternative and terminal complement pathways). INTERVENTION AND COMPARATOR: Patients in the experimental arm will receive daily 32,4 mg Zilucoplan subcutaneously and a daily IV infusion of 2g of the antibiotic ceftriaxone for 14 days (or until hospital discharge, whichever comes first) in addition to standard of care. These patients will receive additional prophylactic antibiotics until 14 days after the last Zilucoplan dose: hospitalized patients will receive a daily IV infusion of 2g of ceftriaxone, discharged patients will switch to daily 500 mg of oral ciprofloxacin. The control group will receive standard of care and a daily IV infusion of 2g of ceftriaxone for 1 week (or until hospital discharge, whichever comes first), to control for the effects of antibiotics on the clinical course of COVID-19. MAIN OUTCOMES: The primary endpoint is the improvement of oxygenation as measured by mean and/or median change from pre-treatment (day 1) to post-treatment (day 6 and 15 or at discharge, whichever comes first) in PaO(2)/FiO(2) ratio, P(A-a)O(2) gradient and a/A PO(2) ratio. (PAO(2)= Partial alveolar pressure of oxygen, PaO(2)=partial arterial pressure of oxygen, FiO(2)=Fraction of inspired oxygen). RANDOMISATION: Patients will be randomized in a 2:1 ratio (Zilucoplan: control). Randomization will be done using an Interactive Web Response System (REDCap). BLINDING (MASKING): In this open-label trial neither participants, caregivers, nor those assessing the outcomes will be blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 81 patients will be enrolled: 54 patients will be randomized to the experimental arm and 27 patients to the control arm. TRIAL STATUS: ZILU-COV protocol Version 4.0 (June 10 2020). Participant recruitment started on June 23 2020 and is ongoing. Given the uncertainty of the pandemic, it is difficult to predict the anticipated end date. TRIAL REGISTRATION: The trial was registered on Clinical Trials.gov on May 11(th), 2020 (ClinicalTrials.gov Identifier: NCT04382755) and on EudraCT (Identifier: 2020-002130-33). FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-020-04884-0. A prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short-and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. Zilucoplan® in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV ) Protocol Co-ordinating Investigator signature page I certify that I will conduct the study in compliance with the protocol, any amendments, GCP and the declaration of Helsinki, and all applicable regulatory requirements. A prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short-and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. Protocol Site Principal Investigator signature page I certify that I will conduct the study in compliance with the protocol, any amendments, GCP and the declaration of Helsinki, and all applicable regulatory requirements. Section 7.1.2: wording changed to "An Investigator must discontinue or withdraw a subject from the study for the following reason." Additional reason for withdrawal from study:  Cases included in the trial with a 'tentative' diagnosis of COVID-19 in which it is not possible to get a confident diagnosis by serology or other means later in the disease course, will be withdrawn from the study as soon as it is clear that SARS-CoV2 was not the cause of the clinical presentation. Clarification added on prophylaxis for meningococcal disease: In all patients that have received Zilucoplan® as a study medication (group A patients), prophylaxis for meningococcal disease using either 3 d generation cephalosporin IV daily or oral ciprofloxacin daily should be continued for 14 days after the last Zilucoplan® dose, even if patient retracted from the study, or was withdrawn from the study by the investigator. In case reason for withdrawal was allergy to an antibiotic, an alternative antibiotic for prophylaxis should be given until 14 days after the last Zilucoplan® dose. Section 9.2, 9.4: Follow up visit week 12-22 after randomization: additional assessments were added: -WHO performance scale -6 minutes walk test (per standard of care) -HRCT scan to evaluate HRCT fibrosis score Section 9.4: -assessment of vital signs: values to be collected at morning assessment, between 7-10 AM for all parameters. -6-point ordinal scale: scoring updated to "1=Death". HRCT fibrosis score: instructions on how to score HRCT findings. Section 13.5: text added: A careful assessment will be performed in cases where disease related events appear to be enhanced by the IMP. In accordance with CT-3 guidance, a causality assessment will be performed for each SAE, and if the investigator considers disease related event to be IMP-related and the event is serious, related and unexpected, then it will be reported as a SUSAR. Section 13.6: Additional information on DSMB Charter: The Charter includes the role of the committee, organizational flow, committee membership, committee meetings and will be signed by all DSMB members prior to the first meeting of the DSMB. Section 9.3, 9.4, 10: details on samples to be collected updated, cfr. updated lab manual provided by central lab, Covance: -DNA to be analysed on EDTA tube instead of PaxGene -PK sample to be collected on D15/discharge -serum samples: 2 x 6 ml instead of 5 ml -6 ml EDTA tube for complement added on D1, D2, D6 and D15/discharge Section 12.1.2 information added that no data will be collected directly into the eCRF. Section 11.1: primary endpoint changed to day 6, day 15 (or discharge). Section 6.1: information added on anti-conception requirements for male subjects. Section 10: D1: samples of 5ml for PK was changed into 6 ml One 6 ml EDTA tube was added for complement (according to flowchart) Section 13.4: in flowchart reporting , 'HIRUZ CTU will inform all participating sites' was added for SUSARs Section 9.2: clinical exam and ECG added to section "at screening", to correspond with 9.4. Improvement of oxygenation as measured by mean and/or median change in normalized PaO2/FiO2 and P(A-a)O2 gradient between enrolment (baseline) and at predose D6 and D15 (or discharge, whichever comes first). The proposed development plan was guided by three specific considerations: 1. Supportive Scientific Rationale: The complement system performs a broad range of functions, including defense against invading pathogens, removal of cellular debris, modulation of adaptive immune system responses, and maintenance of homeostasis. The complement cascade is triggered by diverse mechanisms which lead to the generation of effector molecules that clear susceptible pathogens and cellular debris or promote inflammation, and is also closely regulated. Acute respiratory distress syndrome (ARDS) is characterized by severe, acute inflammatory responses in the lung, resulting in diffuse damage to the alveolar-capillary barrier, flooding the airspaces with protein-rich edema fluid, with severe gas-exchange abnormalities and disordered ventilationperfusion mismatch as a result, leading to profound hypoxia 1 . Among well-known causes of ARDS is viral pneumonia caused by influenza and corona viruses such as SARS-CoV, MERS-CoV and SARS-CoV2. Cytokine responses induced by these viruses can be so excessive, which is known as "cytokine storm", that they not only enhance local inflammatory reactions in the lungs but also induce widespread inflammation elsewhere in the body. ARDS is a frequent complication of COVID-19. It is a main cause of death and the main reason for the current need of intensive care (IC) beds and ventilators to treat patients with SARS-CoV2 infection [2] [3] [4] . Excessive production of cytokines is not the only inflammatory response of the body to severe viral infections. Rather this cytokine storm is part of a broader response involving multiple inflammatory systems. Among the systems activated is the complement system. This system has been studied for decades regarding its role in ARDS. In particular the effects of activated complement on neutrophils leading to their lodging in lung capillaries where they damage the blood-air barrier by releasing oxygen radicals and aggressive proteases, are key in the pathogenesis of ARDS 5,6 . Indirect evidence suggests that complement activation likely contributes to the pathogenesis of ARDS and multiple organ failure (MOF) in COVID-19. A severe viral infection (including influenza, SARS-CoV, MERS-CoV, SARS-CoV2) can trigger a cytokine storm in the lungs and lead to a systemic hyperinflammatory response. Studies in animal models in mice and monkeys for influenza and corona virus-induced lung injury have shown that this leads to activation of complement in the lungs, as evidenced by deposition of several complement factors in the damaged tissues, as well as to an increase of complement activation products in the circulation 7, 8 . Though the exact molecular mechanism of this activation process needs to identified, it likely involves C-reactive protein (CRP) and natural IgM which bind to damaged cells, microparticles, cell debris and molecules released by damaged cells, (ie, damage-associated molecular patterns [DAMPs]), and which subsequently activate complement. The physiological role of this activation is to remove damaged cells and debris via complement receptors on phagocytes. However, in case of excessive activation, complement may do more harm than good, as it further amplifies inflammation and causes additional tissue damage. For example, C3a and C5a, which are generated during complement activation are potent inflammatory peptides, and because of these properties referred to as the anaphylatoxins. C3a and C5a can directly by interaction with their receptors C3aR and C5aR, respectively, interact with endothelial cells and mast cells to increase local vasopermeability. Secondly, C3a and in particular C5a are also chemoattractants that recruit immune effector cells which contributes to lung inflammation. Both recruited monocytes and neutrophils highly express C5aR CD88 in COVID-19 patients. Their effects on neutrophils can be deleterious as they not only recruit these cells to the lungs but also activate and degranulate these cells, leading to further damage of the endothelial-epithelial barrier of the alveoli. Finally, the anaphylatoxins, and also terminal membrane attack complex (MAC, C5b-9) can enhance cytokine responses by mononuclear cells and exacerbate the cytokine storm. Observations in patients with viral pneumonia suggest that the progression towards ARDS is associated with complement activation. Levels of CRP and C4 were significantly increased in patients with SARS. Moreover, levels of C3a and C5a are increased in patients with 2009 H1N1 infection. Furthermore, increased levels of cleaved (presumably activated) C3 distinguish SARS patients from controls, and correlate with LDH and CRP levels. Evidence for complement activation in patients with COVID-19 has recently been documented, showing deposition of MASP2, C4 complement and C5-C9 membrane attack complex in the lungs and skin of 5 patients with severe COVID-19, 2 of which died 9 . Pathological examination suggests that complement activation might be at the heart of a thrombotic microangiopathy that is typically seen in COVID-19 and might be at the basis of increased LDH, thrombocytopenia, mild anemia and elevated D-dimers. The N protein of SARS-CoV2 has the potential to activate MASP-2 and in this way promote the alternative activation of complement 10 . These observations as well as those made in the animal models for virus-induced lung injury, strongly suggest involvement of complement in thrombotic events, acute lung injury, diffuse alveolar damage and ultimately development of ARDS and SIRS during COVID-19 infection. Multiple studies in animal models not only show that virus (influenza, corona)-induced lung injury triggers activation of complement, but also that inhibition of this activation can improve outcome. Deficiency of C3, or inhibition of C5aR or C3aR by receptor antagonist or monoclonal antibody, attenuate virus-induced lung injury in various influenza and SARS models both in mice and monkeys 11, 12 . Notably, these animal studies not only show an improved survival, but also decreased viral load in the lungs 7 . Though experimental evidence for involvement of complement in severe complications of COVID-19 is currently lacking, clinical observations in related syndromes and pathological descriptions of complement deposition at sites of microthrombosis in the lung and skin in COVID-19 patients and data obtained in multiple animal models for virus-induced lung injury, including injury induced by SARS-CoV and MERS-CoV support involvement of complement activation in patients with severe complications of COVID-19. Two small series in COVID-19 patients have reported initial success blocking either C3 complement using AMY101 or C5 complement using eculizumab 13 14 , and one trial is currently underway in China blocking C5a using the antibody BDB-001 (ref 10 ). A genetic association study across 54 countries has identified a polymorphism in complement C3 as a major genetic risk association locus for severity of COVID-19 (Prof Joris De Lange, oral communication). 3. Expediency: Toxicology, pharmacologic and safety data supports the immediate clinical use of Zilucoplan® in hypoxic respiratory failure and ARDS due to COVID-19. Investigator brochure is available and contains detailed information on toxicity. COVID-19 poses a very significant risk of mortality of 3-7% and this percentage rises to mortality of 20% in patients with co-morbidity. Of all infected patients, some 15-20% develop severe respiratory symptoms necessitating hospital admission. Around 5% of infected patients will require invasive mechanical ventilation, and many of those (40-50% will die). The current world-wide pandemic of COVID-19 is putting unforeseen stress on the entire primary, secondary and tertiary medical system, leading to unseen triage of patients that potentially benefit or not from admission to ICU units when they develop respiratory failure. Immune protection against coronavirus infection is understood to rely primarily upon neutralizing humoral immunity and CD8 cytotoxic adaptive T cell cellular immunity, rather than innate immunity and the complement system. Therefore, C5 inhibition is not expected mechanistically to impair the immune response to coronavirus (or indeed to a vaccine once one is available). Treatment with the approved C5 inhibitors eculizumab and ravulizumab, as well as rare genetic deficiencies in C5, are associated with a markedly increased risk for infection with encapsulated bacteria, most notably Neisseria meningitidis and H. influenzae, but not for viral infections generally, or for coronavirus infections in particular. Despite the important potential risk of Neisseria meningitidis, no other important risks have been identified with Zilucoplan®. To prevent the risk of meningococcal disease and prevent other infections with encapsulated bacteria, patients will receive prophylactic antibiotics (e.g. intravenous 3rd generation cephalosporin while in hospital, followed by oral ciprofloxacin upon discharge until 14 days after the last Zilucoplan® administration). Antibiotics that have been used previously to prevent infections under Zilucoplan® in clinical trials include: Cefotaxime ( There is a large number of COVID-19 infected patients that are currently being hospitalized across the globe. In just 30 days time, our COVID-19 ward at Ghent University Hospital has admitted 225 confirmed cases, of which a significant portion (30%) would have fulfilled eligibility criteria for the current proposed protocol. We believe that given the current descending part of the epidemiology curve in Belgium, with numbers of hospital-admitted patients declining rapidly, there will be some delay in obtaining high patient numbers initially. With the release of social distancing measures, and release of government-enforced quarantine measures, the number of cases may increase again after mid May 2020. Justification for our objective is that preventing progression from early acute hypoxic respiratory failure to frank ARDS via complement C5 inhibition could have a huge impact on the overflow of the ICU units, that is happening in some countries and is bound to happen on a global scale. The outcome of our study could thus have large impact from a medical, ethical and economic perspective. The hypothesis of the proposed intervention is that complement C5 has profound effects on acute lung injury present in patients with severe COVID-19 and hypoxia, prior to mechanical intubation, and that C5 inhibition can lead to a 25% improvement in lung oxygenation parameters. The primary objective of this intervention is to study if Zilucoplan® affects the the median and/or mean change in oxygenation between enrolment (baseline) and at predose day 6 and day 15 (or discharge, whichever comes first) through assessment of the PaO2/FiO2 ratio and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID-19 ward or ICU COVID-19 unit. For patients on ECMO the PaO2/FiO2 ratio and Aa-gradient cannot be calculated as in this case the FiO2 will be missing. Therefore, the last available value of PaO2/FiO2 ratio and Aa gradient prior to ECMO can be used at that timepoint. Comparison will be between active group A receiving Zilucoplan® on top of standard of care and control group B receiving standard of care. Prophylaxis against meningococcal disease will be given in group A in the form of IV antibiotic prophylaxis with a third generation cephalosporin (ceftriaxone or cefotaxime while in hospital, followed by oral ciprofloxacin upon discharge until at least 14 days after the last Zilucoplan® dose), since there is no time for immunization against meningococci. To control for the effects of 3d generation cephalosporin on clinical course of COVID-19, the control group B will also receive 1 week (or until hospital discharge whichever comes first) of IV 3rd generation cephalosporin. In case of allergies to these antibiotics, or on clinical indication, these antibiotics may be switched to antibiotics that also cover Neisseria meningitidis. To measure the effectiveness of SC Zilucoplan® treatment on restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation at predose day 6 and day 15 (or at discharge, whichever comes first) through assessment of the mean and/or median change from pretreatment (day 1) to post-treatment (day 6 and 15 or at discharge, whichever comes first) PaO2/FiO2 ratio, P(Aa)O2 gradient and a/A pO2 ratio, which can easily be performed in the setting of clinical observation of patients admitted to the COVID-19 ward or ICU COVID-19 unit. These measurements derived from an arterial blood gas sampling are taken when the patient is sitting upright and breathing room air. Since supplemental oxygen will be indispensable in some patients, the A-a gradient will be normalized against age and FiO2 expected A-a gradient, according to validated formulas. If patients leave hospital between day 6 and day 15, that day of discharge will be taken as measurement point for primary endpoint instead of day 15. For patients on ECMO the PaO2/FiO2 ratio and Aa-gradient cannot be calculated as in this case the FiO2 will be missing. Therefore, the last available value of PaO2/FiO2 ratio and Aa gradient prior to ECMO can be used at that timepoint. This investigator-initiated trial is a phase 2 academic, prospective, 2:1 randomized, open-label, multicenter interventional study designed to investigate the efficacy of subcutaneous Zilucoplan® in improving oxygenation and short-and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. There are currently no treatments reducing lung damage in COVID-19 patients, and no treatment that attempts to halt the progression from manageable acute hypoxic respiratory failure to acute lung injury or ARDS in patients with COVID-19 infection. Justification for our objective is that preventing progression from early acute hypoxic respiratory failure to ARDS could have a huge impact on the foreseeable overflow of the ICU units, that is already happening in some countries and is bound to happen on a global scale. Several academic and non-academic centers in Belgium will participate in this trial. Study coordination, monitoring and data management will be performed under the responsibility of the Health Innovation and Research Institute UZ Ghent (HIRUZ) Clinical Trial Unit and Data Management Unit. The hypothesis of the proposed intervention is that Zilucoplan® has profound effects on inhibiting acute lung injury induced by COVID-19, and can promote lung repair mechanisms, that lead to a 25% We will randomize patients with confirmed COVID19 with acute hypoxic respiratory failure (1. O2 saturation below 93% on minimal 2l/min O2 therapy; and/or 2. PaO2/FiO2 below 350 mmHg) to receive up to 14 days of SC Zilucoplan® on top of standard of care (active group A), or to receive standard of care treatment (control group B). Randomization will be done at a 2:1 ratio active: control group. In the active group A and in the control group B, patients will additionally receive daily antibiotics (daily 3rd generation cephalosporin IV while in hospital, followed by oral ciprofloxacin while discharged) as primary prophylaxis against meningococcal disease until 14 days after the last dose of Zilucoplan®. Control group B will receive standard of care and prophylactic antibiotics (3rd generation cephalosporin IV) for only 1 week (or until hospital discharge whichever comes first), to control for the effects of antibiotics on the clinical course of COVID-19. In case of allergies to these antibiotics, or on clinical indication, these antibiotics may be switched to antibiotics that also cover Neisseria meningitidis. To measure the effectiveness of Zilucoplan® on restoring lung homeostasis, the primary endpoint of this intervention is measuring change in oxygenation parameters comparing baseline values (pretreatment) to values predose day 6 and to values at day 15 (or discharge whichever comes first) post-randomizationin group A and group B and the differences in these values between group A and group B. The subject has completed the study if he or she has completed all phases of the study, including the last visit (week 12-22 post-randomization clinical follow up visit) or the last scheduled procedures, as described in this protocol (see section "9. Study Specific Procedures"). Overall, the end of the study is reached when the last study procedure for the last subject has occurred: last subject, last visit (LSLV). As soon as the whole study has ended (cfr. the definition above), the coordinating investigator shall notify the HIRUZ Clinical Trial Unit, so that the Competent Authority and the Ethics Committee can be informed in a timely manner according to the regulatory requirements (within 90 days after end of the study, or if the study had to be terminated early, this period must be reduced to 15 days and the reasons should clearly explained). We estimate the study to terminate in 52 weeks, including last clinical follow up visits. -COVID-19 diagnosis confirmed by antigen detection test and/or PCR and/or positive serology, or any emerging and validated diagnostic laboratory test for COVID-19 within this period. For patients with a negative SARS-CoV-2 PCR and either a positive SARS-CoV-2 antigen or antibody test, the presence of suggestive lesions for COVID-19 on chest-CT scan is mandatory. -In some patients, it may be impossible to get a confident laboratory confirmation of COVID-19 diagnosis after 24h of hospital admission because viral load is low and/or problems with diagnostic sensitivity. In those cases, in absence of an alternative diagnosis, and with highly suspect bilateral ground glass opacities on recent (<24h) chest-CT scan (confirmed by a radiologist and pulmonary physician as probable COVID-19), and a typical clinical and chemical diagnosis with signs of cytokine release syndrome, a patient can be enrolled as probable SARS-CoV-2-infected. In all cases, this needs confirmation by later seroconversion. -Presence of hypoxia defined as 1)O2 saturation below 93% on minimal 2l/min O2 therapy; and/or 2) PaO2/FiO2 below 350 mmHg (Strongly recommended: patient in upright position, after minimal 3 minutes without supplemental oxygen; In ventilated patients PaO2 can be taken from invasive arterial line and FiO2 taken directly from mechanical ventilation settings). -Signs of acute lung injury and/or cytokine release syndrome defined as ANY of the following -serum ferritin concentration >1000 mcg/L and rising since last 24h -single ferritin above 2000 mcg/L in patients requiring immediate high flow oxygen device (Optiflow) or non-invasive or invasive mechanical ventilation -lymphopenia defined as <800 lymphocytes/microliter and two of the following extra criteria -Ferritin > 700 mcg/L and rising since last 24h -increased LDH (above 300 IU/L) and rising since last 24h -D-Dimers > 1000 ng/mL and rising since last 24h -CRP above 70 mg/L and rising since last 24h and absence of bacterial infection -if three of the above are present at admission, no need to document 24h rise -Low dose Chest CT or HRCT or Angio Chest CT scan showing bilateral infiltrates within last 2 days prior to randomization -Admitted to specialized COVID-19 ward or an ICU ward taking care of COVID-19 patients -Age ≥ 18 years -Women of childbearing potential must have a negative serum pregnancy test pre-dose on day 1. Women of childbearing potential must consistently and correctly use (during the entire treatment period and 4weeks after last Zilucoplan® administration ) at least 1 highly effective method for contraception. Male subjects (who have not been surgically sterilized by vasectomy) must agree to use effective contraception during the study. -Willing and able to provide informed consent or legal representative willing to provide informed consent The number of subjects that will be included in this study is: 81. These are divided into following sub-groups: 54 patients will be randomized to receive daily Zilucoplan® SC for a maximum of 14 days plus prophylactic antibiotics (3rd generation cephalosporin IV, followed by oral ciprofloxacin, or appropriate alternative) daily, maintained for at least 2 weeks after last Zilucoplan® dose)(group A); 27 patients will be randomized to receive standard of care (Group B) plus one week (or until hospital discharge whichever comes first) of 3rd generation cephalosporin IV (or appropriate alternative). The sample size calculation is elaborated in the Statistics section in section 11. Subjects are free to withdraw from participation in the study at any time upon request. If patient decides to leave hospital between day 6 and day 15, treatment with Zilucoplan® will be terminated, and day of discharge will be used to calculate the day 15 endpoint. An investigator must discontinue or withdraw a subject from the study for the following reasons: • allergic reactions (anaphylactic shock) to Zilucoplan® or antibiotic used for prophylaxis of meningococcal disease. Allergy to an antibiotic, should lead to a switch to another antibiotic so that patients receive prophylaxis against meningococcal disease for at least 14 days after the last dose of Zilucoplan®. • Pregnancy • Significant study intervention non-compliance • If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the subject • If the subject meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation  Cases included in the trial with a 'tentative' diagnosis of COVID-19 in which it is not possible to get a confident diagnosis by serology or other means later in the disease course, will be withdrawn from the study as soon as it is clear that SARS-CoV2 was not the cause of the clinical presentation. In all cases, the reason why subjects are withdrawn must be recorded in detail in the eCRF and in the subject's medical records. In all patients that have received Zilucoplan® as a study medication (group A patients), prophylaxis for meningococcal disease using either 3 d generation cephalosporin IV daily or oral ciprofloxacin daily (or appropriate alternative) should be continued for 14 days after the last Zilucoplan® dose, even if patient retracted from the study, or was withdrawn from the study by the investigator. In case reason for withdrawal was allergy to an antibiotic, an alternative antibiotic for prophylaxis should be given until 14 days after the last Zilucoplan® dose. The following actions must be taken if a subject fails to return to the clinic for a required study visit (visit at 12-22 weeks post-randomization): • The site will attempt to contact the subject and reschedule the missed visit within 4 weeks and counsel the subject on the importance of maintaining the assigned visit schedule and ascertain if the subject wishes to and/or should continue in the study. • Before a subject is deemed lost to follow-up, the investigator or designee will make every effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a certified letter to the subject's last known mailing address or local equivalent methods). These contact attempts should be documented in the subject's medical record or study file. • Should the subject continue to be unreachable, he or she will be considered to have withdrawn from the study with a primary reason of lost to follow-up. Subjects will be recruited at the COVID-19 hospitalization ward at the participating centers. The study will be proposed by the treating physician to COVID-19 subjects that fulfill inclusion and exclusion criteria. There will be no compensation for study participation. UCB is providing Zilucoplan® to the study subjects, free of charge. Cost of prophylactic antibiotics will be part of the per patient budget per center and will be purchased by the study site pharmacy. Since this is a hospital-based trial, in which patients are severely ill, we suspect the retention in the trial to be high. Patients will be informed about the study by the treating physician. After receiving full explanation, including the risk of meningococcal disease when blocking C5, having received sufficient time to considerer the trial, asking questions and receiving satisfying responses to all questions, patients will be asked to sign ICF. A serum pregnancy test will be done (female patients of childbearing potential only). Medical history will be checked for review of exclusion criteria and relevant subject information. Patients will be under continuous medical supervision on the COVID-19 ward. Exams (standard of care) include, but are not limited to: -ECG -Low dose chest CT-scan -Laboratory tests for leukocyte formula, kidney and liver function, ferritin levels -Vital signs -Pulse oximetry, Arterial blood gas As soon as all in-and exclusion criteria are checked and patient is considered eligible, patient can be randomized in the RedCAP system. The maximal time window between screening and randomization of the patient is 24h. Zilucoplan® will be supplied by Ra Pharmaceuticals, Inc. as placed within an administration device. Study drug will be packaged and labeled in accordance with applicable local and regulatory requirements. Investigational drug product will be provided in prefilled syringes containing of Zilucoplan® for subcutaneous injection in the abdomen (preferred site), thigh, or upper arm. This dose is equivalent to that administered to the highest weight bracket in prior weight-based dosing regimens and is expected to achieve rapid, profound, and sustained complement inhibition with acceptable safety and tolerability. Subjects who present with very low body weight (<54kg) are excluded from enrolment. Subjects with very high body weight (>150 kg) are also excluded. No dose adjustments and interruptions are permitted during this trial. In case of anaphylaxis or severe AE, the drug will be immediately interrupted. In case a patient is well enough to leave hospital before 14 days of treatment, drug administration will be terminated. Patients on hemodialysis: on days of dialysis the dose of Zilucoplan® should be administered after the procedure is completed. Since a single dose leads to complete complement inhibition within approx. 3h, subjects should continue to be fully complement inhibited even when treated with hemodialysis. If patient undergoes a 24 hours dialysis, it is recommended to administer Zilucoplan® as per protocol while dialysis is ongoing. 14 days, or until hospital discharge, whichever comes first 8.1.6. Packaging and Labeling of the IMP Study drug will be packaged and labeled in accordance with applicable local and regulatory requirements. Via its partner RaPharmaceuticals, UCB had prefilled syringes ready for a Phase III trial in Myastenia gravis in various European countries, labeled on the syringe as RA101495 plus the study number identification. The syringes are too small to be individually relabeled, but the kit containing 7 syringes will be relabeled on the external packaging following communication and as per instructions of FAMHP. All the syringes in the kit will have the same number as on the label on the corrected external packaging, making it possible to link it with the corrected trial reference and sponsor marked on the external packaging. In any case, at the various trial sites, IMP will be administered by study staff, to minimalize errors. The IMP, Zilucoplan®, will be directly delivered to the study sites by UCB in a relabeled format. The study medication should be stored at 2°C to 8°C at the study site. Once dispensed to the hospital ward, Zilucoplan® may be stored at room temperature [20°C to 25°C (68°F to 77°F)] for up to 45 days protected from sources of heat, light, and damage. However, storage of Zilucoplan® outside of room temperatures should be avoided. To date Zilucoplan® has shown a favorable safety and good tolerability profile across all studies in healthy volunteers and patients with gMG, PNH, immune mediated necrotic myopathy (IMNM), and renal impairment. No major safety risks have been identified to date, with over 100 patient years of exposure across and >40,000 injections administered in clinical trials. A difference in the overall adverse event profiles was seen between the clinical trials in different populations: few adverse events occurred in healthy controls and stable renally impaired patients; the adverse event profile in PNH reflected the hemolytic anemia characteristic of the underlying disease; and in the gMG population, many adverse events were reflective of multiple comorbidities, longstanding use of corticosteroid and immunosuppressive therapies, and the more advanced age of this population. Although no meningococcal infections were identified with Zilucoplan® treatment to date, it is well established that inhibition of complement C5 and the terminal complement pathway increases the susceptibility to infection with encapsulated bacteria, in particular Neisseria meningitidis. This risk is also described in the prescribing information for the approved complement C5 inhibitor eculizumab (Soliris® USPI 2017). Given the increased risk for Neisseria meningitidis infection with complement C5 inhibition or deficit, patients who have received Zilucoplan® in ambulatory clinical trials were required to have documentation of Neisseria meningitidis vaccination (and booster if appropriate) prior to treatment initiation. In addition, while on Zilucoplan®, subjects were monitored closely for signs and symptoms of Neisseria meningitidis infection, including self-monitoring based on detailed instruction about signs and symptoms of possible meningococcal infections. Zilucoplan® therapy is not feasible in the context of COVID-19 with hypoxia. Vaccination during the period of COVID-19 with high fever and complement activation, is also not a safe option. Therefore, the risk of neisserial infection must be mitigated by concomitant administration of appropriate antibiotics (e.g. 3rd generation cephalosporin IV, ciprofloxacin PO) from the beginning of Zilucoplan® administration until 14 days after cessation of Zilucoplan®. In the hospital setting this will be achieved by daily IV administration of ceftriaxone (or cefotaxime). As soon as the patient is discharged, oral daily ciprofloxacin will be given until at least 14 days after the last dose of Zilucoplan®. To correct for the effects of antibiotics on the course of COVID-19 disease, the control group B will receive 1 week (or until hospital discharge whichever comes first) of IV ceftriaxone (or cefotaxime) during the hospital stay. In the control group, oral ciprofloxacin post ceftriaxone or cefotaxime is not required. In case of allergies to these antibiotics, or on clinical indication, these antibiotics may be switched to antibiotics that also cover Neisseria meningitidis. There are no restrictions regarding concomitant/rescue medication, except for complement inhibiting drugs or other investigational drugs (see exclusion criteria). Group A patients will receive a daily IV infusion of 2g of ceftriaxone until hospital discharge (or until 28 days after randomization when still in hospital, whichever comes first). If patient is discharged before day 28 after randomization, patient will switch to oral ciprofloxacin 1x500 mg per day until at least 14 days after the last Zilucoplan® administration. In case of unavailability, ceftriaxone can be replaced by cefotaxime 1gr every 8 hours. Group B patients will receive daily IV infusion of 2g of ceftriaxone daily IV during one week or until hospital discharge, whichever comes first. In case of unavailability, ceftriaxone can be replaced by cefotaxime 1g every 8 hours. Prophylactic ceftriaxone will replace any amoxicillin/clavulanic acid that would be given to treat concomitant community acquired pneumonia. In the case that, on clinical grounds, antibiotics need to be switched, in all instances, Neisseria meningitidis and Streptococcus pneumoniae need to be covered by the new antibiotic regimen (e.g. meropenem or piperacillin/tazobactam). In all instances, prophylactic antimeningococcal antibiotics need to be given until at least 14 days after the last Zilucoplan® administration. Patients will be informed about the study by the treating physician. After receiving full explanation, having received sufficient time to considerer the trial, asking questions and receiving satisfying responses to all questions, patients will be asked to sign ICF. The ICF process will be performed before any other study related procedure. In this open label trial patients will be randomized in a 2:1 ratio. Randomization in all centers will be done using REDCap (electronic IWRS system). This is a hospital based intervention trial, in which patients with COVID-19 will be treated for a maximum of 14 days with Zilucoplan®. Patients with COVID-19 infection and respiratory failure are severely ill, and will require multiple daily clinical exams, blood sampling, vital parameter measurements, blood oxygenation measurements, and chest X-rays and/or CT. These are all part of the clinical management plan of the patients, and data stored in the electronic patient file will be used as part of the assessment of efficacy and safety profile of Zilucoplan® At screening, a blood sample will be taken, preferentially during routine blood sampling, to determine exclusion criteria (minimally includes Ferritin, LDH, haptoglobin, D-dimers, CRP, creatinine, triglycerides, fibrinogen, eosinophils, lymphocytes, neutrophils, haemoglobin, WBC count, platelets, bilirubin, ALT and AST, procalcitonin and bHCG (females)). A clinical exam and ECG to be performed at screening or day 1 before administration of study mediation. Any form of chest CT scan within 48h before randomization (low dose, HRCT, or Angio CT scan) must document a presence of bilateral ground glass infiltrates or bilateral consolidation. On day 1, prior to Zilucoplan® treatment in group A, and during the day in group B control patients, two tubes of blood serum (2 x 6 ml), one EDTA 6 ml tube, one 5 ml DNA EDTA tube, and two optional EDTA tubes (2 x 10 ml, optional) will be collected for measuring blood cytokine and chemokine levels, complement, and activation of immune cells. Additionally, one extra EDTA 6 ml tube will be collected from patients in the active group for pharmacokinetics (PK). In both groups, an arterial blood gas determination via arterial puncture will be taken in upright position, after minimal 3 minutes without supplemental oxygen. In case of inability to sit upright: same position should be used for all measurements of PaO2. In ventilated patients or ECMO patients ABG can be obtained from invasive arterial line. In ventilated patients the FiO2 can be directly derived from mechanical ventilation settings. The FiO2 at moment of ABG is documented in the eCRF, except for patients on ECMO.. Scores to be assessed include 6-point ordinal scale, SOFA score and HScore. Both scores to be evaluated at time of first drug administration (Arm A and Arm B). On day 2, one EDTA 6 ml tube for patients in both groups for complement assays (prior to Zilucoplan® treatment in group A) and one tube of blood EDTA (6ml) prior to Zilucoplan® treatment in group A will be collected for pharmacokinetics. On day 6, prior to Zilucoplan® treatment in group A (i.e. pre-dosing) and during the day in group B, two tubes of blood serum (2 x 6ml), plus 1 EDTA 6 ml tube for PK in active group, one EDTA 6 ml tube and two optional EDTA tubes (2 x 10 ml, optional) will be collected for measuring blood cytokine and chemokine levels, complement activation, and activation of immune cells. Additionally, one extra EDTA 6 ml tube will be collected from patients in the active group for PK. Routine laboratory assessment should minimally include Ferritin, LDH, haptoglobin, D-dimers, CRP, creatinine, fibrinogen, eosinophils, lymphocytes, haemoglobin, WBC count, platelets, bilirubin, ALT and AST. Also, an arterial blood gas determination via arterial puncture will be taken in upright position, after minimal 3 minutes without supplemental oxygen. In case of inability to sit upright: same position should be used for all measurements of PaO2. In ventilated patients or ECMO patients ABG can be obtained from invasive arterial line. In ventilated patients the FiO2 can be directly derived from mechanical ventilation settings. The FiO2 at moment of ABG is documented in the eCRF, except for patients on ECMO. Scores to be assessed include 6-point ordinal scale and SOFA score On day 15 (or on discharge whichever comes first), two tubes of blood serum (2 x 6 ml), 1 EDTA 6 ml tube and optional 2 EDTA tubes (2 x 10 ml, optional) will be collected for measuring blood cytokine and chemokine levels, complement activation and activation of immune cells. . Additionally, one extra EDTA 6 ml tube will be collected from patients in the active group for PK. Routine laboratory assessment should minimally include Ferritin, LDH, haptoglobin, D-dimers, CRP, creatinine, fibrinogen, eosinophils, lymphocytes, haemoglobin, WBC count, platelets, bilirubin, ALT and AST. Also, an arterial blood gas determination via arterial puncture will be taken in upright position, after minimal 3 minutes without supplemental oxygen. In case of inability to sit upright: same position should be used for all measurements of PaO2. In ventilated patients or ECMO patients ABG can be obtained from invasive arterial line. In ventilated patients the FiO2 can be directly derived from mechanical ventilation settings. The FiO2 at moment of ABG is documented in the eCRF, except for patients on ECMO. Scores to be assessed include 6-point ordinal scale and SOFA score. Measurements of procalcitonin levels will be performed at least three times per week until day 14, to exclude bacterial infection. On days 1-14 (or until discharge, whichever comes first), patients in group A will receive Zilucoplan® on top of standard of care. They will additionally receive prophylactic antibiotics (IV ceftriaxone during hospital stay followed by daily ciprofloxacin for 14 days after the last Zilucoplan® administration). Patients in control group B will only receive one week of ceftriaxone IV (or until hospital discharge whichever comes first) on top of standard of care, to control for a modifying effect of antibiotics on the clinical course. In case patients in group A and group B would need a switch to another antibiotic for intermittent therapeutic indications, in all instances N. meningitidis, H. Influenzae and S. pneumoniae should be covered in the antibiotic spectrum of the new antibiotic. Patients in groups A or group B who are already receiving amoxicillin/clavulanic acid for treatment of possible bacterial pneumonia co-infection at randomization should be switched to IV ceftriaxone, in order for S. pneumoniae and N. meningitidis to be covered. Upon progression of disease, need for mechanical ventilation and transfer to the ICU within the 14 day period, in patients in the active group, Zilucoplan® will be administered also via SC administration and at all instances presence of edema will be noted. If edema is noted, where possible drug will be administered subcutaneously in non-edematous area, with a preference for the upper leg. At day 28 post-randomization (or within next 3 days) patients will be inquired by phone for 6-point ordinal scale, (S)AE, supplemental oxygen need (Y/N), therapy compliance (antibiotics) and concomitant medication since hospital discharge or day 15. On a final clinical visit between week 12-22 after randomization two additional serum tubes (2 x 6 ml) and optional 2 EDTA tubes (2 x 10 ml) will be taken. Routine laboratory assessment should minimally include Ferritin, LDH, haptoglobin, D-dimers, CRP, creatinine, fibrinogen, eosinophils, lymphocytes, haemoglobin, WBC count, platelets, bilirubin, ALT and AST. Also, an arterial blood gas determination via arterial puncture will be taken. WHO-score, Lung function data (FVC, FEV1, FRC, RV, DLCO), a 6 minute walk test and HRCT scan to assess the HRCT fibrosis score. 1. patient demographics and biometry age, sex, ethnicity, day of admission, weight, length 2. day of confident or highly suspicious COVID-19 diagnosis 3. Clinical and laboratory parameters on screening day and as frequent as possible during trial -first day of illness (defined by myalgia, or fever, or coughing) -clinically relevant abnormalities found during physical examination -vital signs (temperature, blood pressure, heart rate, breathing rate) -pulse oximetry data (SpO2) -clinical blood gas sampling (pH, PaO2, PaCO2, HCO3, SaO2) -clinical chemistry sampling (will be measured on day 1, 6,day 15 or discharge and FU) -Chest X-ray and/or CT characteristics and radiology clinical report 4. All standard care drugs used during the trial and on day of enrolment of the trial, including oxygen flow rate. 5. Basic clinical data on prior medical history (prior lung diseases, smoking history, prior lung function measurements (preferentially within 5 preceding years), prior gas exchange measurements) and medication use will be collected from electronic medical record. 6. Study specific measurements Plasma and serum samples will be collected at each of the indicated timepoints for exploratory analysis that may include but not limited to:  ADA (Day 1, and week 12-22 follow-up)  Complement system assessment on EDTA tube  Cytokines such as will be measured on samples collected at the various centers at day 1, day 6 and day 15 or discharge (whichever comes first)  DNA EDTA tube for pharmacogenomic research (Day 1 predose only) 7. Phamacokinetics (PK) measurements (predose D1, predose D2, predose D6 and D15/discharge) only in group A. m Third generation cephalosporin replaces empiric amoxicillin/clavulanic acid to treat concomitant community acquired pneumonia. In case of allergies or clinical indication for antibiotic switch, N. menigitidis and S. pneumoniae need to be covered by the new antibiotic treatment (e.g. meropenem or piperacilin/tazobactam). Third generation cephalosporin is given until D28 or hospital discharge whichever comes first. n Group B patients receive daily injection of 2g ceftriaxone IV (or appropriate alternative in case of allergies or on clinical indication) during one week or until hospital discharge, whichever comes first. o Upon discharge before D28 post-randomization, patients will switch to daily oral ciprofloxacin (500 mg 1x/d) until at least 14 days after the last dose of Zilucoplan® (only in arm A). p any form of chest CT scan within 48h before randomization (low dose, HRCT, or Angio CT scan) must document a presence of bilateral ground glass infiltrates or bilateral consolidation q HRCT scoring: A subjective assessment of the overall extent of normal attenuation, reticular abnormalities, honeycombing and traction bronchiectasis will be performed. A reticular abnormality is defined as a collection of innumerable areas of small linear opacity. Honeycombing is defined as the presence of a cystic airspace measuring 3-10 mm in diameter, with 1-to 3-mm thick walls. Traction bronchiectasis is defined as irregular bronchial dilatation within the surrounding areas showing parenchymal abnormalities. The morphological criteria on HRCT scans include bronchial dilatation with respect to the accompanying pulmonary artery, a lack of tapering of the bronchi and the identification of bronchi within 10 mm of the pleural surface. The HRCT findings will be graded on a scale of 1-4 based on the classification system: 1. normal attenuation; 2. reticular abnormality; 3. traction bronchiectasis; and 4. honeycombing. The presence of each of the above four HRCT findings will be assessed independently in three (upper, middle and lower) zones of each lung. The upper lung zone is defined as the area of the lung above the level of the tracheal carina, the lower lung zone is defined as the area of the lung below the level of the inferior pulmonary vein and the middle lung zone is defined as the area of the lung between the upper and lower zones. The extent of each HRCT finding will be determined by visually estimating the percentage (to the nearest 5%) of parenchymal involvement in each zone. The score for each zone will be calculated by multiplying the percentage of the area by the grading scale score. The six zone scores will be averaged to determine the total score for each patient. The highest score is 400 points and the lowest score is 100 points using this calculation method. The total score is the "HRCT fibrosis score". (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922654/pdf/1465-9921-15-10.pdf) r WHO performance scale: 0. Able to carry out all normal activity without restrictions; 1. Restricted in physically strenuous activity but ambulatory and able to carry out light work; 2. Ambulatory and capable of all self-care but unable to carry out any work: up and more than 50% of waking hours; 3. Capable of only limited self-care: confined to bed or chair more than 50% if waking hours; 4. Completely disabled: cannot carry on any self-care: totally confined to bed or chair. 10. Sampling 10 .1. Types and number of samples D1: pre-dose serum blood sample 2 x 6ml serum, one EDTA 6ml tube for PK in active group A, one 4 ml DNA EDTA tube, one EDTA 6 ml tube for complement and optional EDTA blood sample, 2 x 10 ml D2: predose 1 x 6ml EDTA tube for PK in active group A only, 1 x 6ml EDTA tube for patients in both groups D6: serum blood sample 2 x 6ml serum tube, one 6 ml EDTA tube for PK in group A, 1 x 6ml EDTA tube for patients in both groups and optional EDTA blood sample, 2 x 10 ml D15 or at discharge: serum blood sample 2 x 6ml, one 6 ml EDTA tube for PK in group A, 1 x 6ml EDTA tube for patients in both groups and optional EDTA blood sample, 2 x 10 ml Week 12-22 post-randomization follow-up visit: serum blood sample 2 x 6ml, optional EDTA blood sample, 2 x 10 ml These samples are to be taken predose on D1, D2, D6 and D15 (or discharge whichever comes first) and on final follow up visit between week 12 and 22. Samples will be taken during hospitalization preferably together with the blood draw for standard of care. For sample handling and analysis, see lab manual provided by Covance. In selected centers (to be decided by the local investigator after consulting with the coordinating principle investigator), additional 2 x 10 ml EDTA blood tubes will be taken at day 1, 6 and 15, or at hospital discharge whichever comes first and safety follow-up, for flow cytometric analysis and local research purposes. The investigators will purify peripheral blood mononuclear cells (PBMC) by gradient centrifugation. Flow cytometry will be performed on paraformaldehyde fixed samples. Results of these trial will be shared with the coordinating principle investigator after analysis. Amongst other, we propose to explore potentially key immunological parameters before and weekly after initiation of experimental therapy to determine 1) their relationship with diseases severity and patient characteristics; 2) their modifications by experimental therapy; 3) their relationship with clinical outcome. The proposal is based on the use of systems biology to 1) explore immunological parameters that cannot be predicted by current knowledge of the immunopathology of the disease; 2) integrate large numbers of parameters in order to be able to identify the most strongly associated with clinical parameters and with the therapeutic intervention. Flow cytometry will be performed on paraformaldehyde fixed samples. For UZ Ghent, this will be done by Flanders Institute of Biotechnology (VIB), in one of their laboratories based at UZ Ghent. Transcriptional program of immune cell populations: EDTA blood samples will be processed to purify peripheral blood mononuclear cells and stained for flow cytometric analysis of number of monocytes, HLA-DR expression on monocytes and dendritic cells, and lymphocyte activation. Whole blood RNA sequencing will be performed to globally assess differences in transcriptional programming of immune cells between patients and modifications following therapy. These data will be used to identify most discordant patient groups and time points on which single cell RNA sequencing (CITE-Seq) will be conducted. On some samples at UZ Ghent for example, a panel of 300 monoclonal antibodies coupled to oligonucleotides, developed by Martin Guilliams at VIB, will be used to identify and phenotype and immune cell populations that will be further analyzed for their transcriptional program, in collaboration with Ido Amit, Weizmann Institute. In selected centres such as UZ Ghent, the plasma fraction of the EDTA blood tube after purification of the PBMC's will be used to measure SARS-CoV-2 RNA using quantitative q-RT-PCR. At UZ Ghent for example, this will be optimized by the virology lab of prof. Linos Vandekerckhove at UZ Ghent and correlated if possible with viral load determined by nasopharyngeal swab detection on D1 and D6 (for patients simultaneously enrolled in the observational CO-VIM trial in UZ Ghent). See lab manual provided by Covance. Optional EDTA samples (selected sites) to be shipped to UZ Ghent. Initially samples will be stored for the use as described within this protocol. If at a later time point samples will be stored for future use, they will be stored in a FAGG certified biobank. The outcome(s) on which the sample size calculation is based upon, is the primary endpoint measurement of oxygenation, defined as ratio of PaO2/FiO2. Sample calculation and power analysis have been performed by statistical consultant Marnik Vuylsteke (Gnomixx) and confirmed by Trevor Smart (UCB statistician). The target difference is the difference measured at the primary endpoint (day 6 and day 15 or discharge) between the control and the treated group. Given a sample size of 81 patients, 54 on Zilucoplan® and standard of care and 27 on standard of care there would be >85% power to show a significant difference from standard of care at the 2 sided 5% level if the true underlying treatment difference was an 80 point difference (25% of 320, being the mean at hospital admission) in the PaO2/FiO2 ratio. This assumes a standard deviation of 105 and a dropout rate of less than 10%. All endpoints will be summarized and where relevant represented graphically Primary endpoint: The change from baseline in PaO2/FiO2 ratio will be analyzed using a Mixed Model Repeated Measures (MMRM) analysis with a fixed effect for Baseline PaO2/FiO2 ratio, treatment, day and treatment by day interaction, where day is categorical. Subject will be fitted as a random effect and an unstructured covariance will be used unless it fails to converge, where other covariance structures will be considered. Other covariates, such as gender, may also be included in the model, if by the time of the analysis these have been identified as key differentiators in terms of COVID-19 recovery. If the variability is shown to be inappropriate for this additive model, then a log transformation of the PaO2/FiO2 ratio may be considered. Data from SOC in another study with a very similar protocol will be incorporated into the analysis using a Bayesian frame work. This will be described more fully in the statistical analysis plan (SAP). A similar analysis for the P(A-a)O2 gradient will be completed Other Endpoints: Other continuous endpoints will be analyzed in a similar way using an MMRM. Response rates, such as 28 day all-cause mortality a logistic regression will be used. Count data will use a generalized linear model with a log link unless the model is either over or under dispersed and then an alternative approach will be used. If it is counts out of a fixed number of days, then a logistic regression will be considered. For the final follow up, a survival analysis with Kaplan-Meir plots will be created covering from Day 1 to end of follow up. The detail around the analyses will be explained in more detail in the SAP and as this is an exploratory study, additional analyses may be considered to explore the data more fully. Interim analyses: will be performed when 42 patients have reached primary endpoint analysis. After half the patients have completed day 15 an interim analysis will be completed to understand if there is already enough evidence to prompt further work on COVID-19 treatment with Zilucoplan®. There is no plan to stop the study at this stage. Analyses will also be completed when all patients have finished day 28 to assess all pre-follow up assessments and 28 day mortality (via phone call). This will enable key results to be understood as soon as possible without compromising the study. The statistical analysis will be performed by Gnomixx, a biostatistics consultancy company based in Ghent (Dr Marnik Vuylsteke). http://www.gnomixx.com/ Subjects that are included in the study at Ghent University Hospital or other Belgian centers, will be assigned a unique study number upon their registration in REDCap. On all documents submitted to the coordinating center, sponsor or CI, patients will only be identified by their study number. The subject identification list will be safeguarded by the site. The name and any other directly identifying details will not be included in the study database. An electronic data capture (EDC) system, i.e. REDCap, will be used for data collection. Data reported on each eCRF should be consistent with the source data. If information is not known, this must be clearly indicated on the eCRF. All missing and ambiguous data will be clarified. Only the data required by the protocol are captured in the eCRF. The eCRFs and the database will be developed, based on the protocol. The final eCRF design will be approved by the Co-ordinating Investigator. All data entries and corrections will only be performed by study site staff, authorized by the investigator. Data will be checked by trained personnel (monitor, data manager) and any errors or inconsistencies will be clarified. The investigator must verify that all data entries in the eCRF are accurate and correct. REDCap is provided and maintained by Vanderbilt University; a license for use was granted to the Health, Innovation and Research Institute (HIRUZ). REDCap is a web-based system intended for academic clinical trials. The study site staff is responsible for data entry in REDCap. All data is to be collected in accordance with the latest version of the ICH E6 (R2) GCP guidelines. There will be no data directly collected in the CRF. The data is accessed through a web browser directly on the secure REDCap server. The server is hosted within the UZ Ghent campus and meets hospital level security and back-up requirements. Privacy and data integrity between the user's browser and the server is provided by mandatory use of Transport Layer Security (TLS), and a server certificate issued by TERENA (Trans-European Research and Education Networking Association). All study sites will have access to REDCap. Site access is controlled with IP restriction. The investigator and sponsor specific essential documents will be retained for at least 25 years. At that moment, it will be judged whether it is necessary to retain them for a longer period, according to applicable regulatory or other requirement(s). Direct access will be granted to authorised representatives from the Sponsor, host institution and the regulatory authorities to permit study-related monitoring, audits and inspections. Pseudonymized biological analyses and study results will also be shared with the provider of Zilucoplan® (UCB Pharma) Login in REDCap is password controlled. Each user will receive a personal login name and password and will have a specific role which has predefined restrictions on what is allowed in REDCap. Furthermore, users will only be able to see data of subjects of their own site. Any activity in the software is traced and transparent via the audit trail and log files. Any untoward medical occurrence in a subject to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An adverse event, the nature or severity of which is not consistent with the applicable product information (e.g., Investigator's Brochure for an unapproved investigational product or package insert/summary of product characteristics for an approved product). Adverse Reaction (AR) An untoward and unintended response in a subject to an investigational medicinal product which is related to any dose administered to that subject. The phrase "response to an investigational medicinal product" means that a causal relationship between a study medication and an AE is at least a reasonable possibility, i.e. the relationship cannot be ruled out. All cases judged by either the reporting medically qualified professional or the Sponsor as having a reasonable suspected causal relationship to the study medication qualify as adverse reactions. A serious adverse event is any untoward medical occurrence that:  results in death  is life-threatening  requires inpatient hospitalisation or prolongation of existing hospitalisation  results in persistent or significant disability/incapacity  consists of a congenital anomaly or birth defect Other 'important medical events' may also be considered serious if they jeopardise the subject or require an intervention to prevent one of the above consequences. NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. An adverse event that is both serious and, in the opinion of the reporting Investigator, believed with reasonable probability to be due to one of the study treatments, based on the information provided. A serious adverse reaction, the nature and severity of which is not consistent with the information about the medicinal product in question set out: SAE's occurring during the entire study period will be reported as below. All serious adverse events (initial and follow up information) and pregnancies occurring during this study must be reported by the local Principal Investigator within 24 hours after becoming aware of the SAE to: -The local ethics committee (it is the responsibility of the local PI to report the local SAE's to the local EC) -HIRUZ CTU of the University Hospital Ghent -The National Coordinating Investigator (in case of multicenter studies) The company UCB that provides the IMP This reporting is done by using the appropriate SAE form. For the contact details, see below. COVID-19 infection is a very recent syndrome, on which few data are available. Normal symptoms and natural disease course symptoms that will not be reported as adverse events are dyspnea, coughing, malaise, fever, drop in oxygen saturation, progression to respiratory failure, progression to ARDS, drop in blood pressure. However, progression to multi-organ failure, may have other etiologies and will be reported as SAE. A careful assessment will be performed in cases where disease related events appear to be enhanced by the IMP. In accordance with CT-3 guidance, a causality assessment will be performed for each SAE, and if the investigator considers disease related event to be IMP-related and the event is serious, related and unexpected, then it will be reported as a SUSAR. Considering the known safety profile of the study medications and study design, however in a new disease indication, a DSMB (chaired by Prof. Sylvie Rottey) is foreseen after enrolment of the first 10 active patients in the trial. The Charter includes the role of the committee, organizational flow, committee membership, committee meetings and will be signed by all DSMB members prior to the first meeting of the DSMB. The Coordinating Investigator will provide DSURs once a year throughout the clinical study, or on request, to the Competent Authority (FAMHP in Belgium), Ethics Committee and Sponsor. This DSUR will include all SAE's (who were not categorized as SAR's and were not immediately reported to the EC). The report will be submitted within 60 days after the start of the study, and will subsequently be submitted each year until the study is declared ended. HIRUZ CTU can provide a template that can be used to complete this DSUR. Monitoring/Auditing/Inspection 14.1. Monitoring Monitoring of the study will be performed in compliance with GCP E6(R2) and the applicable regulatory requirements. The study team will be trained in an initiation visit by the monitor. A training and delegation log will be held. A detailed description of the monitoring tasks can be found in the latest version of the (study-specific) 'Monitoring plan'. Monitoring services will be provided by HIRUZ CTU. All relevant contact details (e.g. primary contact person, can be found in the 'Monitoring plan'. Monitoring services will consist of the following (non-exhaustive list): -review of informed consents and the followed process -check on recruitment status -checking for protocol deviations/violations -checking GCP compatibility -check on safety reporting compliance -IMP handling and storage -review of study data … This study can be inspected at any time by regulatory agencies during or after completion of the study. Therefore access to all study records, including source documents, must be accessible to the inspection representatives. Subject privacy must be respected at all times, in accordance to GDPR, GCP and all other applicable local regulations. The investigator/study team should immediately notify the sponsor if he or she has been contacted by a regulatory agency concerning an upcoming inspection. Sponsor and all investigators agree to take any reasonable actions to correct protocol deviations/violations noted during monitoring/inspection, in consultation with the monitoring team. All deviations must be documented on a protocol deviation log by the study team that is kept available at any time for monitoring/inspection purposes. Under emergency circumstances, deviations from the protocol to protect the rights, safety or well-being of human subjects may proceed without prior approval of the sponsor and the EC. Critical issues that significantly affect patient safety, data integrity and/or study conduct should be clearly documented and will be communicated with the Coordinating Investigator, HIRUZ CTU and possibly both the applicable Ethics Committee(s) and Competent authority. (Please contact HIRUZ CTU asap in case of a serious breach: hiruz.ctu@uzgent.be and/or +3293320500). Early determination of the study (in a specific center or overall) may be necessary in case of major noncompliance. The study will be conducted cfr the latest version of the ICH E6 (R2) GCP guidelines, creating a standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical studies that provides assurance that the data and reported results are accurate and that the rights, integrity and confidentiality of study subjects are protected. Eligible subjects may only be included in the study after providing written (witnessed, if needed) Ethics Committee-approved informed consent, or, if incapable of doing so, after such consent has been provided by a legally acceptable representative(s) of the subject. Informed consent must be obtained before conducting any study-specific procedures (as described in this protocol). Prior to entry in the study, the investigator must explain to potential subjects or their legal representatives the study and the implication of participation. Subjects will be informed that their participation is voluntary and that they may withdraw consent to participate at any time. Participating subjects will be told that their records may be accessed by competent authorities and by authorized persons without violating the confidentiality of the subject, to the extent permitted by the applicable law(s) and/or regulations. By signing the Informed Consent Form (ICF), the subjects or legally acceptable representatives are authorizing such access. After this explanation and before entry to the study, written, dated and signed informed consent should be obtained from the subject or legally acceptable representative. The ICF should be provided in a language sufficiently understood by the subject. Subjects must be given the opportunity to ask questions. The subject or legally acceptable representative will be given sufficient time to read the ICF and to ask additional questions. After this explanation and before entry to the study, consent should be appropriately recorded by means of either the subject's or his/her legal representative's dated signature or the signature of an independent witness who certifies the subject's consent in writing. After having obtained the consent, a copy of the ICF must be given to the subject. In case the subject or legally acceptable representative is unable to read, an impartial witness must attest the informed consent. Subjects who are unable to comprehend the information provided or pediatric subjects can only be enrolled after consent of a legally acceptable representative. Any significant change or addition to the protocol can only be made in a written protocol amendment that must be approved by the Central Ethics Committee (and the FAMHP if applicable). Only amendments that are intended to eliminate an apparent immediate safety threat to patients may be implemented immediately. Notwithstanding the need for approval of formal protocol amendments, the investigators are expected to take any immediate action, required for the safety of any subject included in this study, even if this action represents a deviation from the protocol. These actions should always be notified to the sponsor. All study data will be handled in accordance with the law on General Data Protection Regulation (GDPR) and institutional rules [Belgian law dated on 30 July 2018 and 22 Aug. 2002]. The collection and processing of personal data from subjects enrolled in this study will be limited to those data that are necessary to fulfill the objectives of the study. These data must be collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data privacy protection laws and regulations. Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor and site personnel whose responsibilities require access to personal data agree to keep the identity of subjects confidential. The informed consent obtained from the subject includes explicit consent for the processing of personal data and for the investigator/institution to allow direct access to his or her original medical records (source data/documents) for study-related monitoring, audit, Ethics Committee review and regulatory inspection. This consent also addresses the transfer of the data to other entities, if applicable. Privacy and confidentiality of data generated in the future on stored samples will be protected by the same standards applicable to all other clinical data. Stored samples will be pseudonymized throughout the sample storage and analysis process and will not be labeled with personal identifiers. The sponsor has taken a no fault insurance for this study, in accordance with the relevant legislation (article 29, Belgian Law of May 7, 2004 Acute Respiratory Distress Syndrome Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Pathogenesis of Acute Respiratory Distress Syndrome Biologically active products of complement and acute lung injury in patients with the sepsis syndrome Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis Analysis of complement deposition and viral RNA in placentas of COVID-19 patients Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience Study blood sampling h -2 x 6 ml serum tubes X X X X -1 x 4 ml EDTA tube (DNA) X -2 x 10 ml EDTA tube (optional, selected sites) X X X X -1 x 6 ml EDTA tube (complement) X X X X -1 x 6 ml EDTA tube for PK (arm A only) X X X X -Arterial blood gas X h X i,h X i X Score assessments -6-point ordinal scale j,h Attribution definitions An adverse event is considered associated with the use of the drug if the attribution is possible, probable or definitive, in the opinion of the investigator. An adverse event which is not related to the use of the drug. An adverse event for which an alternative explanation is more likely -e.g. concomitant drug(s), concomitant disease(s), and/or the relationship in time suggests that a causal relationship is unlikely. An adverse event which might be due to the use of the drug. An alternative explanation -e.g. concomitant drug(s), concomitant disease(s), -is inconclusive. The relationship in time is reasonable; therefore the causal relationship cannot be excluded. An adverse event which might be due to the use of the drug. The relationship in time is suggestive (e.g. confirmed by dechallenge). An alternative explanation is less likely -e.g. concomitant drug(s), concomitant disease(s). An adverse event which is listed as a possible adverse reaction and cannot be reasonably explained by an alternative explanation -e.g. concomitant drug(s), concomitant disease(s). The relationship in time is very suggestive (e.g. it is confirmed by dechallenge and rechallenge). AE's will be recorded from the first drug administration until the end of the study, as defined in section 5.2. Special attention will be given to those subjects who have discontinued the study for an AE, or who experienced a severe or a serious AE. All AE's should be recorded in the patient's file and in the CRF.In case the Coordinating Investigator, in consultation with HIRUZ CTU, decides the SAE is a SUSAR (Suspected Unexpected Serious Adverse Reaction), HIRUZ CTU will report the SUSAR to the Central EC and the FAMHP within the timelines as defined in national legislation. The Coordinating Investigator reports the SUSAR to all local PI's. In case of a life-threatening and fatal SUSAR the entire reporting process must be completed within 7 calendar days. In case of a non life-threatening SUSAR the reporting process must be completed within 15 calendar days. This study will be registered at EudraCT and ClinicalStudies.gov, and results information from this study will be submitted to ClinicalStudies.gov. In addition, every attempt will be made to publish results in peer-reviewed journals. 17.